title: [Combined use of local and systemic radiomodifiers as a new modality of cervical carcinoma therapy].
abstract: A cooperative study included 643 cervical carcinoma patients (stage II-III). Radiotherapy used such local and systemic radiomodifiers as DMSO-dissolved metronidazole, which inhibited allopurinol DNA reparations, and dipyridamol, an inductor of interferon synthesis. A 13-15% rise in survival matched the results of combined treatment for cervical carcinoma, yet the simplicity of operation, accessibility, high efficiency and stability of results of our modality made it quite competitive in therapy of the disease.
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Neklasova
authors.forename: G M
authors.initials: GM
authors.lastname: Zharinov
authors.forename: V L
authors.initials: VL
authors.lastname: Vinokurov
authors.forename: G M
authors.initials: GM
authors.lastname: Skrynditsa
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D004121:Dimethyl Sulfoxide; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008795:Metronidazole / Q000627:therapeutic use*; D008875:Middle Aged; D009367:Neoplasm Staging; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D007155:Immunologic Factors; D011838:Radiation-Sensitizing Agents; D008795:Metronidazole; D004121:Dimethyl Sulfoxide